CRISPR Therapeutics Says Trial Data Show CTX112 Has 'Potential' to Treat Malignancies

MT Newswires Live12-10

CRISPR Therapeutics (CRSP) said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well tolerated and induced objective and complete responses at all dose levels.

Five out of the 12 treated patients have achieved responses lasting for more than six months, including one patient whose 6-month response was confirmed after the data cut-off date, according to the company.

"Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol," the company said.

CRISPR also said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Price: 50.78, Change: -1.55, Percent Change: -2.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490058557?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 01:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490058557","market":"sg","top_or_hot":-1,"title":"CRISPR Therapeutics Says Trial Data Show CTX112 Has 'Potential' to Treat Malignancies","media":"MT Newswires Live","content":"<html><body><p> CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CRSP) said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well tolerated and induced objective and complete responses at all dose levels.</p><p>Five out of the 12 treated patients have achieved responses lasting for more than six months, including one patient whose 6-month response was confirmed after the data cut-off date, according to the company.</p><p>\"Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol,\" the company said.</p><p>CRISPR also said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.</p><p>Price: 50.78, Change: -1.55, Percent Change: -2.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CRISPR Therapeutics Says Trial Data Show CTX112 Has 'Potential' to Treat Malignancies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCRISPR Therapeutics Says Trial Data Show CTX112 Has 'Potential' to Treat Malignancies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 01:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CRISPR Therapeutics (CRSP) said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490058557","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490058557","pubTimestamp":1733766381,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CRISPR Therapeutics  said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well tolerated and induced objective and complete responses at all dose levels.Five out of the 12 treated patients have achieved responses lasting for more than six months, including one patient whose 6-month response was confirmed after the data cut-off date, according to the company.\"Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol,\" the company said.CRISPR also said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.Price: 50.78, Change: -1.55, Percent Change: -2.97","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4585":"ETF&股票定投概念","LENZ":"Therapeutics","BK4556":"基因编辑","BK4139":"生物科技","BK4588":"碎股","CRSP":"CRISPR Therapeutics AG","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"CRISPR Therapeutics表示试验数据显示CTX112具有治疗恶性肿瘤的“潜力”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"LENZ":1},"content_text":"CRISPR Therapeutics (CRSP) said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well tolerated and induced objective and complete responses at all dose levels.Five out of the 12 treated patients have achieved responses lasting for more than six months, including one patient whose 6-month response was confirmed after the data cut-off date, according to the company.\"Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol,\" the company said.CRISPR also said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.Price: 50.78, Change: -1.55, Percent Change: -2.97","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490058557"}